IL6 and obesity disorder: Therefore, in the future IL-6 (such as selective inhibition of IL-6 trans-signaling) can be targeted as a potential therapeutic option for treating obesity and metabolic disorders (affecting adipose tissue and impairments of skeletal muscle glucose uptake) as well as for autoimmune and inflammatory conditions.